Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia
Status:
Completed
Trial end date:
1989-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if giving azidothymidine (AZT) to HIV-positive patients
with hemophilia is safe and if it is effective in lowering HIV levels and boosting the immune
system.
HIV infects and inactivates certain blood cells that are part of the body's immune system.
The damage to the body's immune system can result in unusual infections and/or unusual forms
of cancer. A large percentage of hemophiliacs are HIV-positive and there is a clear risk for
the development of AIDS in these patients. AZT may be effective in lowering HIV levels and
boosting the immune system but its side effects are not understood in these patients.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)